Showing results (651-660 of 667) with videos related to
Sort By:
Pageof 67
Molecular Genetics and Metabolism|October 3, 2002
Seventeen novel mutations that cause profound biotinidase deficiencyB Wolf, K Jensen, G Hüner, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 23, 2026
Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samplesTyler L Borko, Alanna Ritchie, Sean Selva, et al.European Urology|January 27, 2016
Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy SpecimenJan P Radtke, Constantin Schwab, Maya B Wolf, et al.Nature Communications|June 28, 2022
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaLing Tao, Mahmoud A Mohammad, Giorgio Milazzo, et al.Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.Neurology|November 14, 2024
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic IndicationsCarson M Quinn, Prashanth Rajarajan, Alexander J Gill, et al.Blut|September 1, 1981
Germinal center cell lymphomas: prognostic significance of their histopathological differentiationE König, H Bartels, K Bremer, et al.Molecular Cancer Therapeutics|December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid TumorsMelissa L Johnson, Beni B Wolf, Judy S Wang, et al.The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2018
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCA Lisberg, A Cummings, J W Goldman, et al.Pageof 67